Zoetis (NYSE:ZTS) has been assigned a $85.00 price objective by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 17.50% from the stock’s current price.
ZTS has been the subject of a number of other research reports. BMO Capital Markets set a $65.00 price objective on Zoetis and gave the company a “hold” rating in a research report on Wednesday, October 25th. BidaskClub upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Cowen set a $80.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Friday, November 17th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a report on Wednesday, November 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $68.82.
Zoetis (NYSE:ZTS) opened at $72.34 on Tuesday. The firm has a market capitalization of $35,070.00, a PE ratio of 38.07, a PEG ratio of 2.16 and a beta of 1.06. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a 12-month low of $52.00 and a 12-month high of $73.58.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in Zoetis by 2,471.1% during the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after buying an additional 34,679,064 shares during the period. Morgan Stanley increased its holdings in Zoetis by 182.5% during the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after buying an additional 9,442,207 shares during the period. Janus Henderson Group PLC increased its holdings in Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after buying an additional 5,734,776 shares during the period. Norges Bank purchased a new position in Zoetis during the fourth quarter valued at approximately $273,651,000. Finally, Winslow Capital Management LLC purchased a new position in Zoetis during the fourth quarter valued at approximately $228,438,000. 93.19% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Zoetis (ZTS) Given a $85.00 Price Target at Cantor Fitzgerald” was first reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/27/zoetis-zts-given-a-85-00-price-target-at-cantor-fitzgerald.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
